TARGET trial of intranasal sumatriptan

 

REPORT FROM THE 67TH AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING – WASHINGTON DC, APRIL 18-25, 2015 – The TARGET trial evaluated low-dose sumatriptan powder delivered intranasally using a breath-powered device (AVP-825) in patients with acute migraine (McAllister et al. AAN 2015; abstract P1.300; full results published as Cady et al. Headache 2015;55:88-100).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page